Altrius Capital Management Inc Grows Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Altrius Capital Management Inc lifted its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 4.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 46,609 shares of the biopharmaceutical company’s stock after purchasing an additional 1,785 shares during the period. Altrius Capital Management Inc’s holdings in Bristol-Myers Squibb were worth $2,981,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of BMY. Dakota Wealth Management purchased a new stake in Bristol-Myers Squibb in the first quarter worth about $332,000. Covestor Ltd boosted its position in shares of Bristol-Myers Squibb by 111.5% during the first quarter. Covestor Ltd now owns 2,052 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 1,082 shares in the last quarter. NewEdge Advisors LLC grew its stake in Bristol-Myers Squibb by 53.2% in the first quarter. NewEdge Advisors LLC now owns 165,336 shares of the biopharmaceutical company’s stock worth $12,075,000 after purchasing an additional 57,444 shares during the period. Ergoteles LLC bought a new position in Bristol-Myers Squibb in the first quarter worth $1,997,000. Finally, Mackenzie Financial Corp lifted its position in Bristol-Myers Squibb by 25.1% during the first quarter. Mackenzie Financial Corp now owns 338,563 shares of the biopharmaceutical company’s stock valued at $24,725,000 after buying an additional 68,018 shares during the period. 74.98% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on BMY. Wells Fargo & Company decreased their price target on shares of Bristol-Myers Squibb from $78.00 to $65.00 and set an “equal weight” rating for the company in a research note on Friday, July 28th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Bristol-Myers Squibb in a research note on Thursday, November 9th. They set a “hold” rating and a $55.00 target price for the company. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Friday, October 27th. HSBC upgraded Bristol-Myers Squibb from a “reduce” rating to a “hold” rating and lowered their price objective for the company from $55.00 to $53.00 in a research note on Friday, October 27th. Finally, Atlantic Securities reduced their price target on Bristol-Myers Squibb from $90.00 to $85.00 and set an “overweight” rating for the company in a report on Friday, July 28th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $63.59.

Bristol-Myers Squibb Stock Performance

BMY stock traded down $1.44 during trading on Monday, reaching $49.40. The stock had a trading volume of 9,773,258 shares, compared to its average volume of 9,659,062. The firm has a market cap of $100.52 billion, a PE ratio of 12.63, a PEG ratio of 1.62 and a beta of 0.38. The company has a current ratio of 1.18, a quick ratio of 1.07 and a debt-to-equity ratio of 1.11. The stock’s 50 day moving average is $55.60 and its two-hundred day moving average is $60.85. Bristol-Myers Squibb has a 52 week low of $48.78 and a 52 week high of $81.43.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.00 earnings per share for the quarter, topping the consensus estimate of $1.76 by $0.24. The firm had revenue of $10.97 billion for the quarter, compared to analysts’ expectations of $10.96 billion. Bristol-Myers Squibb had a net margin of 18.44% and a return on equity of 51.59%. The business’s quarterly revenue was down 2.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.99 EPS. As a group, equities analysts anticipate that Bristol-Myers Squibb will post 7.56 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th were given a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 4.62%. The ex-dividend date was Thursday, October 5th. Bristol-Myers Squibb’s payout ratio is 57.87%.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Ann Powell sold 17,986 shares of the business’s stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $61.25, for a total transaction of $1,101,642.50. Following the completion of the sale, the executive vice president now owns 27,868 shares of the company’s stock, valued at $1,706,915. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.09% of the stock is currently owned by company insiders.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.